Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC)

Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC)

It is still not possible for all patients with early breast cancer to be cured. Even when they respond well to initial therapy, there exists a substantial risk for recurrence, sometimes after several years. With the availability of cyclin-dependent kinase (CDK) 4/6 inhibitors the role of adjuvant th...

Full description

Saved in:
Bibliographic Details
Main Authors: Purvish M. Parikh, Amish Vora, Rajan Yadav, Akhil Kapoor, Tarini Sahoo, Senthil Rajappa, Govind Babu Kanakashetty, M. Vamshi Krishna, Ghanashyam Biswas, Ankur Bahl, Nikhil Ghadyalpatil, Thirumalairaj Raja, Jyoti Bajpai, Amol Akhade, Randeep Singh, Shyam Aggarwal, Maheboob Basade, S.H. Advani
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2025-01-01
Series:South Asian Journal of Cancer
Subjects:
targeted therapy
IDFS
high risk
regulatory approval
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1791768
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1791768

Similar Items